Antibiotic developer Allecra Therapeutics GmbH has raised €22 million (US$24.7 million) in a series B round to fully fund phase II trials for AAI202, a combination of a beta-lactam antibiotic together with a proprietary, extended-spectrum beta-lactamase inhibitor designed to treat gram-negative multidrug-resistant bacterial infections.